コンテンツへスキップ
Merck

911860

NanoFabTx microfluidic - micro

device kit for synthesis of 1-5 μm particles

別名:

Microfluidic kit, Microparticle, NanoFabTx device kit, Nanoformulation

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

NACRES:
NA.23
UNSPSC Code:
12162002
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


description

Microfludic device kit for synthesizing 1-5 μm microparticles

Kit components :

  • Microfluidic chip x 1
  • Tubings and accessories

Quality Segment

application(s)

advanced drug delivery

General description

NanoFabTx Microfluidic - micro device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and accessories—a microfluidic platform to synthesize drug-encapsulating microparticles 1-5 μm in size. It is compatible with either a standard syringe pump (not included) or the Dolomite microfluidics system (not included). The device kit does not include reagents. NanoFabTx- micro reagent kits, like NanoFabTx PLGA-micro (Cat.No. 912220) provide the reagents for the synthesis of 1-5 μm PLGA microparticles.

Application

NanoFabTx Microfluidic - micro device kit is designed to work with the NanoFabTx- micro reagent kits for the synthesis of 1-5 μm particles (Cat.No. 912220) and can be used to create drug-encapsulated polymeric microspheres with narrow size-dispersity and consistent drug loading. Polymeric microparticles also can encapsulate larger biologics like proteins, mRNA, and DNA, in addition to drugs and small molecules, and may serve as vehicles for targeted delivery and controlled release. Microfluidic-based synthesis is a powerful tool in drug development for fabricating size-controlled drug-delivery particles, enabling scalable synthesis of particles and rapid formulation screening. In contrast to nanoprecipitation or solvent-displacement methods, microfluidic technologies have several advantages including enhanced reproducibility, less consumption of expensive reagents, and superior scalability.

Features and Benefits

  • Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
  • Optimized to make monodisperse microparticles of any size between 1 and 5 μm
  • Facilitates simple optimization of drug encapsulation and loading efficiency in microparticles

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC


Still not finding the right product?

Explore all of our products under NanoFabTx microfluidic - micro




最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする


資料

Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.

Microfluidic assembly improves polyamine nanoencapsulation of nucleic acids, overcoming challenges like polydispersity and poor reproducibility.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

すべての記事を見る

関連コンテンツ


Samar Damiati et al.
Genes, 9(2) (2018-02-22)
Microfluidic devices present unique advantages for the development of efficient drug carrier particles, cell-free protein synthesis systems, and rapid techniques for direct drug screening. Compared to bulk methods, by efficiently controlling the geometries of the fabricated chip and the flow
Andrew Gdowski et al.
Journal of nanobiotechnology, 16(1), 12-12 (2018-02-13)
The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the parameters used in the original formulation must be
Xuanyu Li et al.
Advanced drug delivery reviews, 128, 101-114 (2017-12-27)
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods.